Comparable Safety Profiles of IV and Subcutaneous Immunotherapy in Advanced Melanoma

This segment discusses the safety and side effect profiles of intravenous and subcutaneous immunotherapy in advanced melanoma. Dr. Morrison and Ms. Popolo emphasize that both administration methods have similar safety profiles, with no major differences in systemic side effects. Patients are counseled on the same potential immune-related adverse events, including skin, gastrointestinal, endocrine, and respiratory effects, and are monitored through routine laboratory assessments. Ms. Popolo highlights that the primary distinction with subcutaneous administration is the potential for mild injection site reactions, such as redness, soreness, or localized inflammation. Ms. Haupert shares her personal experience, noting that she experienced a mild injection site reaction that was effectively managed with diphenhydramine and ice packs. Dr. Morrison provides additional context, explaining that these localized reactions are typically manageable and short-lived. Overall, the discussion reinforces that while the route of administration differs, safety monitoring and patient counseling remain consistent in advanced melanoma care.